dotMD.com
Join Community
📖Formal Study Breakdown Talk in Diabetes, Thyroid & A1C Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. See how members lowered A1C, timed Metformin ER, and optimized thyroid labs—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Diabetes, Thyroid & A1C Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Diabetes, Thyroid & A1C Space →
Back to Plain-English 8th-Grade Story
Google Scholar NIH PubMed #42815506
Official NIH NLM MEDLINE / PubMed Citation • PMID: 42815506

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet

Verbatim Formal Study Abstract

Between May 1, 2023, and Sept 5, 2024, 2749 participants were randomly assigned (1371 to orforglipron and 1378 to insulin glargine).